“Broadly Maligning This Group No Longer Warranted,” goes the title of a note on specialty pharma from Piper Jaffray.
“Can a specialty pharma deep value idea really work in 2020,” asks the team. “We think so,” they answer themselves, upgrading Endo Pharmaceuticals (NASDAQ:ENDP) to Overweight, with $7 price target (56% upside).
Notable Calls notes this is the first upgrade for Endo in two years, and this “coiled spring” could see something nearing a $5 handle today.
Shares are higher by 2% premarket to $4.59
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.